|
DE3360633D1
(en)
*
|
1982-02-12 |
1985-10-03 |
Unitika Ltd |
Anti-cancer device
|
|
US4389393A
(en)
*
|
1982-03-26 |
1983-06-21 |
Forest Laboratories, Inc. |
Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
|
|
DE3435325A1
(de)
*
|
1983-04-09 |
1986-04-17 |
Nikken Chemicals Co., Ltd., Tokio/Tokyo |
Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
|
|
US4591500A
(en)
*
|
1983-04-25 |
1986-05-27 |
Microencapsulation S.A. |
Tablet having the shape of a capsule, process and device for its preparation
|
|
US4571333A
(en)
*
|
1983-06-14 |
1986-02-18 |
Syntex (U.S.A.) Inc. |
Controlled release naproxen and naproxen sodium tablets
|
|
JPH0662404B2
(ja)
*
|
1983-06-14 |
1994-08-17 |
シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド |
制御放出性ナプロキセンおよびナプロキセンナトリウム錠
|
|
IL72381A
(en)
*
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
|
JPS6038322A
(ja)
*
|
1983-08-11 |
1985-02-27 |
Fujisawa Pharmaceut Co Ltd |
ジヒドロピリジンａ物質含有易溶性固形製剤
|
|
US4680323A
(en)
*
|
1983-12-01 |
1987-07-14 |
Hans Lowey |
Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
|
|
FR2556965B1
(fr)
*
|
1983-12-21 |
1986-08-22 |
Rhone Poulenc Sante |
Nouvelle forme galenique du ketoprofene a liberation controlee
|
|
GB8403360D0
(en)
*
|
1984-02-08 |
1984-03-14 |
Erba Farmitalia |
Pharmaceutical compositions
|
|
CH666406A5
(de)
*
|
1984-02-29 |
1988-07-29 |
Sandoz Ag |
Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
|
|
GB2154874B
(en)
*
|
1984-02-29 |
1987-11-04 |
Sandoz Ltd |
Bromoscriptine compositions
|
|
US4795327A
(en)
*
|
1984-03-26 |
1989-01-03 |
Forest Laboratories, Inc. |
Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
|
|
US4540566A
(en)
*
|
1984-04-02 |
1985-09-10 |
Forest Laboratories, Inc. |
Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
|
|
GB8414220D0
(en)
*
|
1984-06-04 |
1984-07-11 |
Sterwin Ag |
Medicaments in unit dose form
|
|
US4532244A
(en)
*
|
1984-09-06 |
1985-07-30 |
Innes Margaret N |
Method of treating migraine headaches
|
|
AU592065B2
(en)
*
|
1984-10-09 |
1990-01-04 |
Dow Chemical Company, The |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4695464A
(en)
*
|
1984-10-09 |
1987-09-22 |
The Dow Chemical Company |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4678516A
(en)
*
|
1984-10-09 |
1987-07-07 |
The Dow Chemical Company |
Sustained release dosage form based on highly plasticized cellulose ether gels
|
|
US4639458A
(en)
*
|
1985-01-22 |
1987-01-27 |
Merck & Co., Inc. |
Tablet and formulation
|
|
AT388101B
(de)
*
|
1985-02-05 |
1989-05-10 |
Sandoz Ag |
Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur oralen verabreichung mit kontrollierter wirkstofffreisetzung
|
|
HU195729B
(en)
*
|
1985-02-05 |
1988-07-28 |
Sandoz Ag |
Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
|
|
AU598751B2
(en)
*
|
1985-02-07 |
1990-07-05 |
Novartis Ag |
Pharmaceutical formulations with controlled release of the active substance
|
|
US4601894A
(en)
*
|
1985-03-29 |
1986-07-22 |
Schering Corporation |
Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
|
|
US4695591A
(en)
*
|
1985-03-29 |
1987-09-22 |
Schering Corporation |
Controlled release dosage forms comprising hydroxypropylmethylcellulose
|
|
US4657757A
(en)
*
|
1985-03-29 |
1987-04-14 |
Schering Corporation |
Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
|
|
US4885173A
(en)
*
|
1985-05-01 |
1989-12-05 |
University Of Utah |
Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
|
|
EP0227814A1
(en)
*
|
1985-07-02 |
1987-07-08 |
The Upjohn Company |
Therapeutic formulations with bimodal release characteristics
|
|
GB8518301D0
(en)
*
|
1985-07-19 |
1985-08-29 |
Fujisawa Pharmaceutical Co |
Hydrodynamically explosive systems
|
|
GB2181053B
(en)
*
|
1985-10-01 |
1990-05-23 |
Sandoz Ltd |
Pharmaceutical formulations with controlled release of the active substance
|
|
HU197201B
(en)
*
|
1985-10-01 |
1989-03-28 |
Sandoz Ag |
Process for producing oral pharmaceutical compositions of controlled solubility of the active components
|
|
IT1187750B
(it)
*
|
1985-10-15 |
1987-12-23 |
Eurand Spa |
Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
|
|
US4734285A
(en)
*
|
1985-10-28 |
1988-03-29 |
The Dow Chemical Company |
Sustained release compositions
|
|
US4704285A
(en)
*
|
1985-11-18 |
1987-11-03 |
The Dow Chemical Company |
Sustained release compositions comprising hydroxypropyl cellulose ethers
|
|
IE63321B1
(en)
*
|
1986-02-03 |
1995-04-05 |
Elan Corp Plc |
Drug delivery system
|
|
GB2186485B
(en)
*
|
1986-02-13 |
1988-09-07 |
Ethical Pharma Ltd |
Slow release formulation
|
|
IT1191674B
(it)
*
|
1986-03-07 |
1988-03-23 |
Eurand Spa |
Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
|
|
US4662880A
(en)
*
|
1986-03-14 |
1987-05-05 |
Alza Corporation |
Pseudoephedrine, brompheniramine therapy
|
|
GB8608080D0
(en)
*
|
1986-04-02 |
1986-05-08 |
Fujisawa Pharmaceutical Co |
Solid dispersion composition
|
|
US4855143A
(en)
*
|
1986-04-04 |
1989-08-08 |
Hans Lowey |
Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
|
|
US4775535A
(en)
*
|
1986-04-04 |
1988-10-04 |
Hans Lowey |
Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
|
|
US4780320A
(en)
*
|
1986-04-29 |
1988-10-25 |
Pharmetrix Corp. |
Controlled release drug delivery system for the periodontal pocket
|
|
JPS62286925A
(ja)
*
|
1986-06-06 |
1987-12-12 |
Terumo Corp |
水酸化アルミニウムゲルを含有する外用薬組成物
|
|
EP0249347B1
(en)
*
|
1986-06-10 |
1994-06-29 |
Euroceltique S.A. |
Controlled release dihydrocodeine composition
|
|
US4832957A
(en)
*
|
1987-12-11 |
1989-05-23 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
|
NZ220599A
(en)
*
|
1986-06-16 |
1990-10-26 |
Merck & Co Inc |
Controlled release oral dosage formulation of carbidopa and levodopa
|
|
JPS6310702A
(ja)
*
|
1986-07-01 |
1988-01-18 |
Ube Ind Ltd |
徐放化製剤の製造方法
|
|
US4861590A
(en)
*
|
1986-09-25 |
1989-08-29 |
Colgate-Palmolive Company |
Sustained release fluoride and calcium composition
|
|
US4859467A
(en)
*
|
1986-09-25 |
1989-08-22 |
Colgate-Palmotive Company |
Sustained release fluoride composition
|
|
US4851233A
(en)
*
|
1986-10-06 |
1989-07-25 |
Warner-Lambert Company |
Sustained release formulations
|
|
DE3639073A1
(de)
*
|
1986-11-14 |
1988-05-26 |
Klinge Co Chem Pharm Fab |
Feste arzneizubereitungen und verfahren zu ihrer herstellung
|
|
US4752470A
(en)
*
|
1986-11-24 |
1988-06-21 |
Mehta Atul M |
Controlled release indomethacin
|
|
US4822629A
(en)
*
|
1986-12-12 |
1989-04-18 |
Norwich Eaton Pharmaceuticals, Inc. |
Azumolene dosage form
|
|
US4869908A
(en)
*
|
1987-01-09 |
1989-09-26 |
K.V. Pharmaceutical Co. |
Fibre formulations
|
|
US5015479A
(en)
*
|
1987-02-02 |
1991-05-14 |
Seamus Mulligan |
Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
|
|
US4851232A
(en)
*
|
1987-02-13 |
1989-07-25 |
Alza Corporation |
Drug delivery system with means for obtaining desirable in vivo release rate pattern
|
|
US4810502A
(en)
*
|
1987-02-27 |
1989-03-07 |
Alza Corporation |
Pseudoephedrine brompheniramine therapy
|
|
US5023076A
(en)
*
|
1987-02-27 |
1991-06-11 |
Alza Corporation |
Lamina comprising carboxyvinyl polymer
|
|
US4915952A
(en)
*
|
1987-02-27 |
1990-04-10 |
Alza Corporation |
Composition comprising drug, HPC, HPMC and PEO
|
|
EP0281200B1
(en)
*
|
1987-03-02 |
1994-01-19 |
Yamanouchi Europe B.V. |
Pharmaceutical composition, pharmaceutical granulate and process for their preparation
|
|
US4789549A
(en)
*
|
1987-03-09 |
1988-12-06 |
Warner-Lambert Company |
Sustained release dosage forms
|
|
US4786503A
(en)
*
|
1987-04-06 |
1988-11-22 |
Alza Corporation |
Dosage form comprising parallel lamine
|
|
US5500228A
(en)
*
|
1987-05-26 |
1996-03-19 |
American Cyanamid Company |
Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
|
|
US6645504B1
(en)
*
|
1987-06-24 |
2003-11-11 |
Autoimmune Inc. |
Bystander suppression of type I diabetes by oral administration of glucagon
|
|
EP0297866A3
(en)
*
|
1987-07-01 |
1989-12-13 |
The Boots Company PLC |
Therapeutic agents
|
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
|
IE60311B1
(en)
*
|
1987-09-24 |
1994-06-29 |
American Home Prod |
Sustained release etodolac
|
|
US4837030A
(en)
*
|
1987-10-06 |
1989-06-06 |
American Cyanamid Company |
Novel controlled release formulations of tetracycline compounds
|
|
US4871731A
(en)
*
|
1987-10-07 |
1989-10-03 |
Marion Laboratories, Inc. |
Captopril and diltiazem composition and the like
|
|
IE64726B1
(en)
*
|
1987-11-20 |
1995-08-23 |
Elan Corp Plc |
Pharmaceutical formulations for preventing drug tolerance
|
|
US4983398A
(en)
*
|
1987-12-21 |
1991-01-08 |
Forest Laboratories, Inc. |
Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
|
|
GB8802391D0
(en)
*
|
1988-02-03 |
1988-03-02 |
Ddsa Pharmaceuticals Ltd |
Medicinal formulations
|
|
US4931285A
(en)
*
|
1988-04-28 |
1990-06-05 |
Alza Corporation |
Aqueous based pharmaceutical coating composition for dosage forms
|
|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
|
US5160743A
(en)
*
|
1988-04-28 |
1992-11-03 |
Alza Corporation |
Annealed composition for pharmaceutically acceptable drug
|
|
US5096714A
(en)
*
|
1988-06-28 |
1992-03-17 |
Hauser-Kuhrts, Inc. |
Prolonged release drug tablet formulations
|
|
IT1229203B
(it)
*
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5268181A
(en)
*
|
1989-04-13 |
1993-12-07 |
Upsher-Smith Laboratories, Inc. |
Method of using niacin to control nocturnal cholesterol synthesis
|
|
US5126145A
(en)
*
|
1989-04-13 |
1992-06-30 |
Upsher Smith Laboratories Inc |
Controlled release tablet containing water soluble medicament
|
|
GB8913889D0
(en)
*
|
1989-06-16 |
1989-08-02 |
May & Baker Ltd |
New compositions of matter
|
|
AU652723B2
(en)
*
|
1989-08-25 |
1994-09-08 |
Bioglan Laboratories Ltd. |
Pharmaceutical compositions and a device for administering the same
|
|
US5198228A
(en)
*
|
1989-09-14 |
1993-03-30 |
Hoechst-Roussel Pharmaceuticals Inc. |
Direct dry compressible acetaminophen tablet
|
|
US5037658A
(en)
*
|
1989-09-14 |
1991-08-06 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Direct dry compressible acetaminophen composition
|
|
US5130140A
(en)
*
|
1989-09-14 |
1992-07-14 |
Hoeschst-Roussel Pharmaceuticals Inc. |
Method of making direct dry compressible acetaminophen composition
|
|
US5476668A
(en)
*
|
1990-08-24 |
1995-12-19 |
Shin-Etsu Chemical Co., Ltd. |
Base for film-coating pharmaceuticals and method for preparing same
|
|
SE9003904D0
(sv)
*
|
1990-12-07 |
1990-12-07 |
Astra Ab |
Method for the manufacture of a pharmaceutical dosage form
|
|
US5770588A
(en)
*
|
1991-02-11 |
1998-06-23 |
The Research Foundation Of State University Of New York |
Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
|
|
US5223248A
(en)
*
|
1991-02-11 |
1993-06-29 |
The Research Foundation Of State University Of New York |
Non-antibacterial tetracycline compositions possessing antiplaque properties
|
|
US5204116A
(en)
*
|
1991-05-01 |
1993-04-20 |
Alza Corporation |
Dosage form providing immediate therapy followed by prolonged therapy
|
|
CA2067975C
(en)
*
|
1991-05-20 |
2003-01-14 |
Cynthia M. Blase |
Buffered matrix aspirin tablet
|
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
US5266331A
(en)
†
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
|
NL9102142A
(nl)
|
1991-12-20 |
1993-07-16 |
Dagra Pharma Bv |
Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
|
|
ES2115638T3
(es)
*
|
1991-12-30 |
1998-07-01 |
Akzo Nobel Nv |
Composicion tiroactiva de liberacion controlada.
|
|
US5700485A
(en)
*
|
1992-09-10 |
1997-12-23 |
Children's Medical Center Corporation |
Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
|
|
US5922340A
(en)
*
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
|
PT659073E
(pt)
*
|
1992-09-10 |
2002-06-28 |
Childrens Medical Center |
Matrizes polimericas biodegradaveis para entrega sustentada de agentes anestesicos locais
|
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
|
NZ260408A
(en)
|
1993-05-10 |
1996-05-28 |
Euro Celtique Sa |
Controlled release preparation comprising tramadol
|
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
|
NZ268003A
(en)
*
|
1993-06-14 |
1996-11-26 |
Janssen Pharmaceutica Nv |
Extended release coated tablets comprising pseudoephedrine in a coated core, the coating comprising pseudoephedrine and astemizole intermediate an inner extended release coating and an outer seal coating
|
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
|
US6129930A
(en)
*
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
|
US5484607A
(en)
*
|
1993-10-13 |
1996-01-16 |
Horacek; H. Joseph |
Extended release clonidine formulation
|
|
AU7961094A
(en)
*
|
1993-10-19 |
1995-05-08 |
Procter & Gamble Company, The |
Picosulphate dosage form
|
|
US5451409A
(en)
*
|
1993-11-22 |
1995-09-19 |
Rencher; William F. |
Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
|
|
US5891471A
(en)
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
|
KR100354702B1
(ko)
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
|
HUT71408A
(en)
*
|
1994-01-14 |
1995-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
|
|
US5843480A
(en)
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
|
US5478572A
(en)
*
|
1994-09-06 |
1995-12-26 |
Bristol-Myers Squibb Co. |
Gepirone dosage form
|
|
US5968983A
(en)
*
|
1994-10-05 |
1999-10-19 |
Nitrosystems, Inc |
Method and formulation for treating vascular disease
|
|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
|
US6425881B1
(en)
*
|
1994-10-05 |
2002-07-30 |
Nitrosystems, Inc. |
Therapeutic mixture useful in inhibiting lesion formation after vascular injury
|
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
|
US5728402A
(en)
*
|
1994-11-16 |
1998-03-17 |
Andrx Pharmaceuticals Inc. |
Controlled release formulation of captopril or a prodrug of captopril
|
|
US6103263A
(en)
*
|
1994-11-17 |
2000-08-15 |
Andrx Pharmaceuticals, Inc. |
Delayed pulse release hydrogel matrix tablet
|
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
|
US5736159A
(en)
*
|
1995-04-28 |
1998-04-07 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
|
|
WO1996041616A1
(en)
*
|
1995-06-09 |
1996-12-27 |
Euro-Celtique, S.A. |
Formulations and methods for providing prolonged local anesthesia
|
|
US5614207A
(en)
*
|
1995-06-30 |
1997-03-25 |
Mcneil-Ppc, Inc. |
Dry mouth lozenge
|
|
WO1997004752A1
(en)
*
|
1995-07-26 |
1997-02-13 |
Duramed Pharmaceuticals, Inc. |
Pharmaceutical compositions of conjugated estrogens and methods for their use
|
|
PT861073E
(pt)
*
|
1995-11-14 |
2004-10-29 |
Abbott Gmbh & Co Kg |
Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las
|
|
US6274171B1
(en)
|
1996-03-25 |
2001-08-14 |
American Home Products Corporation |
Extended release formulation of venlafaxine hydrochloride
|
|
PE57198A1
(es)
*
|
1996-03-25 |
1998-10-10 |
American Home Prod |
Formula de liberacion prolongada
|
|
US20060068017A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
|
US20030215507A1
(en)
*
|
1996-03-25 |
2003-11-20 |
Wyeth |
Extended release formulation
|
|
US5948437A
(en)
*
|
1996-05-23 |
1999-09-07 |
Zeneca Limited |
Pharmaceutical compositions using thiazepine
|
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
AU733867B2
(en)
|
1996-06-24 |
2001-05-31 |
Euro-Celtique S.A. |
Methods for providing safe local anesthesia
|
|
US6046187A
(en)
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
|
CA2275604A1
(en)
*
|
1997-01-03 |
1998-07-09 |
Kenneth Iain Cumming |
Sustained release cisapride mini-tablet formulation
|
|
US6004932A
(en)
*
|
1997-03-06 |
1999-12-21 |
Iowa State University Research Foundation, Inc. |
Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
|
|
US7179486B1
(en)
|
1997-04-01 |
2007-02-20 |
Nostrum Pharmaceuticals, Inc. |
Process for preparing sustained release tablets
|
|
CA2216215A1
(en)
*
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
|
US6551616B1
(en)
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US6010718A
(en)
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
|
US6210710B1
(en)
|
1997-04-28 |
2001-04-03 |
Hercules Incorporated |
Sustained release polymer blend for pharmaceutical applications
|
|
CA2271750C
(en)
|
1997-07-02 |
2004-04-27 |
Euro-Celtique, S.A. |
Prolonged anesthesia in joints and body spaces
|
|
US5895663A
(en)
*
|
1997-07-31 |
1999-04-20 |
L. Perrigo Company |
Pseudoephedrine hydrochloride extended-release tablets
|
|
IN186245B
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
ZA989356B
(en)
*
|
1997-10-16 |
1998-11-16 |
Isis Pharma Gmbh |
Pharmaceutical preparations
|
|
US5948440A
(en)
*
|
1997-12-17 |
1999-09-07 |
Ranbaxy Laboratories Limited |
Modified release matrix formulation of cefaclor and cephalexin
|
|
WO1999047128A1
(en)
|
1998-03-19 |
1999-09-23 |
Bristol-Myers Squibb Company |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method
|
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
|
US6043259A
(en)
*
|
1998-07-09 |
2000-03-28 |
Medicure Inc. |
Treatment of cardiovascular and related pathologies
|
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
|
US6106862A
(en)
*
|
1998-08-13 |
2000-08-22 |
Andrx Corporation |
Once daily analgesic tablet
|
|
US6214381B1
(en)
|
1998-09-08 |
2001-04-10 |
Effcon, Inc. |
Methazolamide composition and method of use
|
|
DE19842753A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
|
US20020169145A1
(en)
*
|
1998-10-14 |
2002-11-14 |
Rajen Shah |
Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
|
|
US6416786B1
(en)
|
1998-12-11 |
2002-07-09 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
|
US6419953B1
(en)
|
1998-12-18 |
2002-07-16 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US20020025341A1
(en)
*
|
1998-12-18 |
2002-02-28 |
Yihong Qiu |
Controlled release formulation of divalproex sodium
|
|
US6511678B2
(en)
|
1998-12-18 |
2003-01-28 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6528090B2
(en)
|
1998-12-18 |
2003-03-04 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6713086B2
(en)
|
1998-12-18 |
2004-03-30 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
US6150410A
(en)
*
|
1999-02-04 |
2000-11-21 |
Abbott Laboratories |
pH independent extended release pharmaceutical formulation
|
|
JP2002539127A
(ja)
|
1999-03-08 |
2002-11-19 |
メディキュア インコーポレーテッド |
ビタミンｂ−６障害のためのピリドキサル類縁体
|
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
|
US6489345B1
(en)
*
|
1999-07-13 |
2002-12-03 |
Medicure, Inc. |
Treatment of diabetes and related pathologies
|
|
PL356667A1
(en)
*
|
1999-08-20 |
2004-06-28 |
Ferrosan A/S |
A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
|
|
EP1872797A3
(en)
*
|
1999-08-24 |
2008-04-02 |
Medicure International Inc. |
Treatment of cardiovascular and related pathologies
|
|
US7771746B2
(en)
*
|
1999-12-03 |
2010-08-10 |
Polichem Sa |
Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
|
|
US20050037073A1
(en)
*
|
2000-01-13 |
2005-02-17 |
Alpharx Inc. |
Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
|
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
|
ES2240419T3
(es)
|
2000-02-29 |
2005-10-16 |
Medicure International Inc. |
Fosfonatos protectores del corazon.
|
|
US7442689B2
(en)
*
|
2000-02-29 |
2008-10-28 |
Medicure International Inc. |
Cardioprotective phosphonates and malonates
|
|
AU784840B2
(en)
|
2000-03-28 |
2006-07-06 |
Medicure International Inc. |
Treatment of cerebrovascular disease
|
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
|
US6242003B1
(en)
*
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
|
WO2002004421A2
(en)
|
2000-07-07 |
2002-01-17 |
Medicure International Inc. |
Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
|
|
US6897228B2
(en)
*
|
2000-07-07 |
2005-05-24 |
Medicure International Inc. |
Pyridoxine and pyridoxal analogues: new uses
|
|
US6548519B1
(en)
|
2001-07-06 |
2003-04-15 |
Medicure International Inc. |
Pyridoxine and pyridoxal analogues: novel uses
|
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
|
AU2002220248A1
(en)
*
|
2000-11-06 |
2002-05-15 |
Andrx Pharmaceuticals, Inc. |
Once a day antihistamine and decongestant formulation
|
|
AUPR549901A0
(en)
*
|
2001-06-06 |
2001-07-12 |
Vital Health Sciences Pty Ltd |
Topical formulation containing tocopheryl phosphates
|
|
JP2004513183A
(ja)
*
|
2000-11-14 |
2004-04-30 |
バイタル ヘルス サイエンシズ プロプライアタリー リミティド |
リン酸誘導体の複合体
|
|
WO2002051402A1
(en)
*
|
2000-12-22 |
2002-07-04 |
Abbott Laboratories |
Controlled release formulation of divalproex sodium
|
|
JP2004521111A
(ja)
*
|
2001-01-25 |
2004-07-15 |
ユーロ−セルティーク，エス．エイ． |
局所麻酔薬および使用法
|
|
US20020103110A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Spitzer A. Robert |
System and method for rectal administration of medication for treatment of migraines
|
|
BR0207297A
(pt)
*
|
2001-02-15 |
2005-04-19 |
King Pharmaceuticals Inc |
Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
|
US20040121988A1
(en)
*
|
2001-03-28 |
2004-06-24 |
Medicure International Inc. |
Treatment of cerebrovascular disease
|
|
US20060127474A1
(en)
*
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
|
GB0118300D0
(en)
*
|
2001-07-26 |
2001-09-19 |
Cortendo Ab |
Formulations
|
|
BR0211673A
(pt)
*
|
2001-07-27 |
2004-07-13 |
Vital Health Sciences Pty Ltd |
Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
US20030180356A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
AU2002350272B1
(en)
*
|
2001-12-13 |
2003-06-23 |
Vital Health Sciences Pty Ltd |
Transdermal transport of compounds
|
|
EP1455751A1
(en)
*
|
2001-12-20 |
2004-09-15 |
Pharmacia Corporation |
Zero-order sustained released dosage forms and method of making the same
|
|
US20030162769A1
(en)
*
|
2002-02-26 |
2003-08-28 |
Easterling W. Jerry |
Composition and method for treating vulvodynia
|
|
US20050176782A1
(en)
*
|
2002-02-26 |
2005-08-11 |
Easterling W. J. |
Medicament and method for treating vulodynia
|
|
EP1513503A1
(en)
*
|
2002-06-07 |
2005-03-16 |
Ranbaxy Laboratories Limited |
Extended release formulation of divalproex sodium
|
|
WO2003105810A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
|
AU2002950713A0
(en)
*
|
2002-08-09 |
2002-09-12 |
Vital Health Sciences Pty Ltd |
Carrier
|
|
WO2004028507A1
(en)
*
|
2002-09-24 |
2004-04-08 |
Akzo Nobel N.V. |
Method to improve pharmaceutical tablets having a matrix of cellulose ether
|
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
|
US8092831B2
(en)
*
|
2002-11-08 |
2012-01-10 |
Andrx Pharmaceuticals, Llc |
Antihistamine and decongestant system
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
ATE534384T1
(de)
*
|
2003-01-17 |
2011-12-15 |
Vital Health Sciences Pty Ltd |
Verbindungen mit proliferationshemmenden eigenschaften
|
|
SE0302947D0
(sv)
*
|
2003-01-24 |
2003-11-07 |
Magle Ab |
A composition material for transmucosal delivery
|
|
US20040156893A1
(en)
*
|
2003-02-11 |
2004-08-12 |
Irwin Klein |
Method for treating hypothyroidism
|
|
US20040186077A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Medicure International Inc. |
Novel heteroaryl phosphonates as cardioprotective agents
|
|
AU2003901815A0
(en)
*
|
2003-04-15 |
2003-05-01 |
Vital Health Sciences Pty Ltd |
Phosphate derivatives
|
|
WO2004104022A2
(en)
*
|
2003-05-16 |
2004-12-02 |
The General Hospital Corporation |
Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
|
|
US20040241234A1
(en)
*
|
2003-06-02 |
2004-12-02 |
Alpharma, Inc. |
Controlled release press-coated formulations of water-soluble active agents
|
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
|
PL1638529T3
(pl)
*
|
2003-06-16 |
2017-03-31 |
Andrx Pharmaceuticals, Llc. |
Kompozycja doustna o przedłużonym uwalnianiu
|
|
EP1648418A4
(en)
*
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
|
|
US8313775B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
|
US8313776B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
|
AU2004264939A1
(en)
*
|
2003-08-11 |
2005-02-24 |
Middlebrook Pharmaceuticals, Inc. |
Robust pellet
|
|
EP1653924A4
(en)
|
2003-08-12 |
2009-09-09 |
Middlebrook Pharmaceuticals In |
ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
|
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
JP2007513869A
(ja)
*
|
2003-09-15 |
2007-05-31 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
|
AU2004308419B2
(en)
*
|
2003-12-24 |
2011-06-02 |
Victory Pharma, Inc. |
Enhanced absorption of modified release dosage forms
|
|
EP1718621A4
(en)
|
2004-01-30 |
2009-08-19 |
Univ Johns Hopkins |
NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
|
|
DE602005025979D1
(de)
*
|
2004-03-03 |
2011-03-03 |
Vital Health Sciences Pty Ltd |
Alkaloid-formulierungen
|
|
EP1765336A4
(en)
|
2004-06-25 |
2010-03-10 |
Univ Johns Hopkins |
ANGIOGENESIS INHIBITORS
|
|
EP1771158A4
(en)
*
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSE DISTRIBUTION
|
|
CN101014357A
(zh)
*
|
2004-07-07 |
2007-08-08 |
麦迪库瑞国际公司 |
利用血小板聚集药物的组合疗法
|
|
US20070060549A1
(en)
*
|
2004-08-10 |
2007-03-15 |
Friesen Albert D |
Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
|
|
US8747895B2
(en)
*
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
US20060068004A1
(en)
*
|
2004-09-28 |
2006-03-30 |
Aum Nutrapharm Inc. |
Buccal delivery of sea cucumber tablets
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
ES2409347T3
(es)
|
2004-10-21 |
2013-06-26 |
Aptalis Pharmatech, Inc. |
Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
|
|
JP2008517956A
(ja)
*
|
2004-10-28 |
2008-05-29 |
メディキュア・インターナショナル・インコーポレーテッド |
二重の抗血小板性／抗凝固性ピリドキシン類似体
|
|
US7459468B2
(en)
*
|
2004-10-28 |
2008-12-02 |
Medicure International, Inc. |
Aryl sulfonic pyridoxines as antiplatelet agents
|
|
US20060094749A1
(en)
*
|
2004-10-28 |
2006-05-04 |
Medicure International Inc. |
Substituted pyridoxines as anti-platelet agents
|
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
|
EP1853272A1
(en)
*
|
2005-02-03 |
2007-11-14 |
Duramed Pharmaceuticals, Inc. |
Compositions of unconjugated estrogens and methods for their use
|
|
BRPI0607999A2
(pt)
*
|
2005-03-03 |
2009-10-27 |
Vital Health Sciences Pty Ltd |
método para o alìvio de sintomas, o tratamento ou a prevenção do cáncer, uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais hidróxi cromanos selecionados do grupo que consiste em 7:8-dimetil 6-hidróxi cromanos (delta), 8-metil 6-hidróxi cromanos (gama), e as misturas dos mesmos, conjuntamente com um veìculo ou um diluente apropriado, método para a indução da apoptose celular, método para aumentar a eficácia de um agente anticáncer, método para aumentar a eficácia do licopeno, formulação farmacêutica
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
US9168216B2
(en)
*
|
2005-06-17 |
2015-10-27 |
Vital Health Sciences Pty. Ltd. |
Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
|
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
|
US9192615B2
(en)
|
2008-08-06 |
2015-11-24 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
|
US7544373B2
(en)
*
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
|
US20080242642A1
(en)
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
WO2007016338A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Use of chk2 kinase inhibitors for cancer treatment
|
|
KR20080047375A
(ko)
|
2005-07-29 |
2008-05-28 |
콘서트 파마슈티컬즈, 인크. |
약제 화합물
|
|
US20070149485A1
(en)
*
|
2005-11-28 |
2007-06-28 |
Medicure International, Inc. |
Selected dosage for the treatment of cardiovascular and related pathologies
|
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
|
BRPI0621081A2
(pt)
*
|
2005-12-23 |
2011-11-29 |
Vital Health Sciences Pty Ltd |
método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos
|
|
US20070160667A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Nava Shterman |
Controlled release formulation of divalproex sodium
|
|
DE602006003848D1
(de)
|
2006-01-11 |
2009-01-08 |
Teva Pharma |
Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
|
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
|
TWI405567B
(zh)
*
|
2006-06-01 |
2013-08-21 |
Merck Sharp & Dohme |
持續釋放脫羥腎上腺素之醫藥組合物
|
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
|
US7538652B2
(en)
*
|
2006-08-29 |
2009-05-26 |
International Business Machines Corporation |
Electrical component tuned by conductive layer deletion
|
|
US20120178810A1
(en)
*
|
2006-09-11 |
2012-07-12 |
Tailor Prakash Boya |
Extended release formulation of an antiepileptic agent
|
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
|
US20080220064A1
(en)
*
|
2006-12-06 |
2008-09-11 |
Ramesh Ketkar Anant |
Extended release matrix formulations of morphine
|
|
WO2008073388A2
(en)
*
|
2006-12-11 |
2008-06-19 |
Mutual Pharmaceutical Company, Inc. |
Alfuzosin formulations, methods of making and methods of use
|
|
WO2008088881A1
(en)
|
2007-01-19 |
2008-07-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
|
WO2008102235A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Aurobindo Pharma Limited |
Controlled release formulations of alfuzosin
|
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
|
US20080287418A1
(en)
*
|
2007-05-16 |
2008-11-20 |
Astrazeneca Ab |
Extended Release Compositions and Methods for Their Manufacture
|
|
KR20100020459A
(ko)
*
|
2007-06-08 |
2010-02-22 |
아드레넥스 파마슈티컬스, 아이엔씨. |
지연 방출형 제제 및 아드레날린 조절부전의 치료방법
|
|
US20100172991A1
(en)
*
|
2007-06-08 |
2010-07-08 |
Henry Joseph Horacek |
Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
|
|
KR100836960B1
(ko)
|
2007-09-07 |
2008-06-10 |
주식회사 서울제약 |
새로운 나이아신 제어방출형 제제
|
|
ES2670665T3
(es)
|
2008-06-19 |
2018-05-31 |
Xcovery Holding Company Llc |
Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de quinasa
|
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
|
US20120190748A1
(en)
*
|
2009-08-04 |
2012-07-26 |
Haren Treasurer |
Greater utility with thyroid hormone
|
|
MX350056B
(es)
|
2009-11-03 |
2017-08-25 |
Lupin Ltd |
Formulacion de liberacion modificada de lacosamida.
|
|
WO2011067667A2
(en)
|
2009-12-02 |
2011-06-09 |
Eurand Pharmaceuticals Limited |
Fexofenadine microcapsules and compositions containing them
|
|
ES2999020T3
(en)
|
2010-02-05 |
2025-02-24 |
Phosphagenics Ltd |
Carrier comprising non-neutralised tocopheryl phosphate
|
|
KR20130010473A
(ko)
|
2010-03-30 |
2013-01-28 |
포스파제닉스 리미티드 |
경피 전달 패치
|
|
JP6023062B2
(ja)
|
2010-10-08 |
2016-11-09 |
エックスカバリー ホールディング カンパニー エルエルシー |
置換ピリダジンカルボキサミド化合物
|
|
WO2012100208A1
(en)
|
2011-01-20 |
2012-07-26 |
Bionevia Pharmaceuticals Inc. |
Modified release compositions of epalrestat or a derivative thereof and methods for using the same
|
|
WO2012122586A1
(en)
|
2011-03-15 |
2012-09-20 |
Phosphagenics Limited |
New composition
|
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
|
KR102341899B1
(ko)
|
2013-04-07 |
2021-12-21 |
더 브로드 인스티튜트, 인코퍼레이티드 |
개인맞춤화 신생물 백신을 위한 조성물 및 방법
|
|
WO2014192918A1
(ja)
*
|
2013-05-31 |
2014-12-04 |
久光製薬株式会社 |
口腔貼付剤
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
ITMI20132065A1
(it)
*
|
2013-12-11 |
2015-06-12 |
Farmatron Ltd |
Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
GB201506755D0
(en)
|
2015-04-21 |
2015-06-03 |
Reckitt Benckiser Llc |
Novel pharmaceutical formulation
|
|
CA2936746C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016187508A2
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute Inc. |
Shared neoantigens
|
|
CA3001337C
(en)
|
2015-10-09 |
2023-12-12 |
Reckitt Benckiser Llc |
Pharmaceutical formulation
|
|
CA3007587C
(en)
|
2015-12-09 |
2023-12-05 |
Phosphagenics Limited |
Pharmaceutical formulation
|
|
CA3008170A1
(en)
|
2015-12-30 |
2017-07-06 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of seizure-related disorders
|
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
|
EA201990523A1
(ru)
|
2016-10-03 |
2019-10-31 |
|
НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
|
|
ES2983921T3
(es)
|
2016-12-21 |
2024-10-28 |
Avecho Biotechnology Ltd |
Proceso para fosforilar un alcohol complejo
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
US9980946B1
(en)
|
2017-01-25 |
2018-05-29 |
Effcon Laboratories, Inc. |
Extended release methazolamide formulation
|
|
US10695309B2
(en)
|
2017-03-31 |
2020-06-30 |
Western New England University |
Sustained-release liothyronine formulations, method of preparation and method of use thereof
|
|
AU2019264232A1
(en)
|
2018-05-04 |
2020-11-12 |
Tollys |
TLR3 ligands that activate both epithelial and myeloid cells
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US20220289999A1
(en)
*
|
2019-07-11 |
2022-09-15 |
StenCo, LLC |
Biodegradable material
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
JP2023528805A
(ja)
|
2020-05-26 |
2023-07-06 |
ディオニス セラピューティクス インコーポレイテッド |
核酸人工ミニプロテオームライブラリー
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
WO2023016321A1
(zh)
|
2021-08-10 |
2023-02-16 |
贝达药业股份有限公司 |
恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
|
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|
|
WO2025126109A1
(en)
|
2023-12-15 |
2025-06-19 |
Ensem Therapeutics, Inc. |
Anilino-pyrazole derivatives, compositions and methods thereof
|